Tempest Therapeutics, Inc.
TPSTHealthcare|Biotechnology|US
$0.38
+0.01 (+1.44%)
Cash / Share
$0.05
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04524871 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Advanced Liver Cancers | P1P2 | Active | 518 | RCT, Open-label | Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg |
| NCT06680258 A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | Hepatocellular Carcinoma (HCC) | P3 | Not Yet Recruiting | 740 | RCT, Double-blind | TPST-1120, Atezolizumab, Bevacizumab |
| NCT04344795 Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | Solid Tumor, Colorectal Cancer | P1 | Completed | 89 | Open-label | TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab |
| NCT03829436 TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer | P1 | Completed | 38 | Open-label | Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab |